Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis

Podobne knjige/članki

• Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
  od: Taylor, P, et al.
  Izdano: (2020)
• Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
  od: Taylor, P, et al.
  Izdano: (2020)
• Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
  od: Taylor, P, et al.
  Izdano: (2019)
• Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
  od: Taylor, PC, et al.
  Izdano: (2020)
• Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
  od: Vishal R. Tandon, et al.
  Izdano: (2022-07-01)